These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28723807)

  • 1. Can patients with femoral neck fracture benefit from preoperative thromboprophylaxis?: A prospective randomized controlled trial.
    Li Q; Dai B; Xu J; Yao Y; Song K; Zhang H; Chen D; Jiang Q
    Medicine (Baltimore); 2017 Jul; 96(29):e7604. PubMed ID: 28723807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
    Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
    Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban versus fondaparinux for thromboprophylaxis after endovenous laser ablation.
    Keo HH; Baumann F; Diehm N; Regli C; Staub D
    J Vasc Surg Venous Lymphat Disord; 2017 Nov; 5(6):817-823. PubMed ID: 29037351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
    Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
    Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rivaroxaban on preventing deep vein thrombosis in aged diabetics with femoral neck fractures after hip replacement.
    Zhang YM; Jiang X; Sun YS
    Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28442600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial.
    Wang JW; Chen B; Lin PC; Yen SH; Huang CC; Kuo FC
    J Arthroplasty; 2017 Mar; 32(3):801-806. PubMed ID: 27663190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma D-dimer is not useful in the prediction of deep vein thrombosis after total knee arthroplasty in patients using rivaroxaban for thromboprophylaxis.
    Wu CT; Chen B; Wang JW; Yen SH; Huang CC
    J Orthop Surg Res; 2018 Jul; 13(1):173. PubMed ID: 29996862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk assessment and management of preoperative venous thromboembolism following femoral neck fracture.
    Xia ZN; Xiao K; Zhu W; Feng B; Zhang BZ; Lin J; Qian WW; Jin J; Gao N; Qiu GX; Weng XS
    J Orthop Surg Res; 2018 Nov; 13(1):291. PubMed ID: 30458869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.
    Vadhan-Raj S; McNamara MG; Venerito M; Riess H; O'Reilly EM; Overman MJ; Zhou X; Vijapurkar U; Kaul S; Wildgoose P; Khorana AA
    Cancer Med; 2020 Sep; 9(17):6196-6204. PubMed ID: 32663379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
    Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
    J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effectiveness and Safety of Rivaroxaban and Edoxaban in the Treatment of Lower Extremity Deep Vein Thrombosis.
    Wang L; Luo Z; Yang L; Li W
    Ann Vasc Surg; 2024 Nov; 108():246-256. PubMed ID: 38960092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
    Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
    BMJ Open; 2018 Jun; 8(6):e020286. PubMed ID: 29934383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial.
    Kang JM; Park KH; Ahn S; Cho S; Han A; Lee T; Jung IM; Kim JY; Min SK
    Sci Rep; 2019 Dec; 9(1):20356. PubMed ID: 31889152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
    Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
    Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
    Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
    JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial.
    Ramacciotti E; Agati LB; Calderaro D; Volpiani GG; de Oliveira CCC; Aguiar VCR; Rodrigues E; Sobreira ML; Joviliano EE; Dusilek C; Itinose K; Dedivitis RA; Cortina AS; Sanches SMV; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; Cavalcante BBM; Moreira RCR; Chiann C; Tafur A; Spyropoulos AC; Lopes RD
    Am Heart J; 2021 Dec; 242():115-122. PubMed ID: 34480880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials.
    Ning GZ; Kan SL; Chen LX; Shangguan L; Feng SQ; Zhou Y
    Sci Rep; 2016 Mar; 6():23726. PubMed ID: 27020475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.